LeMaitre Vascular, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2022
July 28, 2022 at 04:05 pm EDT
Share
LeMaitre revised earnings guidance for the fourth quarter and full year of 2022. For the fourth quarter, the company expects sales $41.2 million - $43.2 million. EPS of $0.29 to $0.35.
For the year, the company expects sales $162.7 million - $165.3 million. EPS of $0.99 to $1.05.
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
LEMAITRE VASCULAR, INC. 
